Inapparent Infections with Junin Virus among Laboratory Workers

Weissenbacher, Mercedes; Grela, Maria E.; Sabattini, Marta S.; Maiztegui, Julio I.; Coto, Celia E.; Frigerio, M. J.; Cossio, Patricio M.; Rabinovich, Adriana; Oro, Julio G. Barrera

doi:10.1093/infdis/137.3.309

Cited by 13 publications

(12 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The causative agent, Junin virus, is a member of the Arenaviridae family. Infection with this virus is generally symptomatic in humans (24,26), with death occurring in 15 to 30% of untreated individuals (11,18). Human immune plasma has been shown to be effective in reducing mortality to <1% when administered within 8 days of the appearance of clinical illness (3,12).…”

mentioning

confidence: 99%

Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic fever

McKee

Huggins

Trahan

et al. 1988

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Junin virus-infected rhesus macaques received prophylactic and therapeutic ribavirin to assess the potential of this drug for treating humans with Argentine hemorrhagic fever. When ribavirin was administered intramuscularly at the time of experimental infection with the lethal P3790 strain of Junin virus, all animals were protected from clinical disease. A delay in the initiation of therapy until after the onset of illness resulted in improvement and resolution of systemic signs of disease; however, survivors subsequently developed a late-onset central nervous system infection which was fatal in two of three animals. Side effects of ribavirin included thrombocytosis and severe anemia, both of which resolved promptly on withdrawal of drug therapy. Results of this study suggest that ribavirin may prove useful in treating humans with Argentine hemorrhagic fever.

show abstract

mentioning

confidence: 99%

Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic fever

McKee

Huggins

Trahan

et al. 1988

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Previous studies had shown that Junin virus produces inapparent infection in human beings, both among rural workers of the endemic area and also among laboratory personnel working with Junin virus [Weissenbacher et al, 1976;Weissenbacher et al, 1978;Weissenbacher et al, 1980;Guerrero et al, 19821. The results of the present study demonstrate that the prevalence of inapparent infection is lower than that of clinical infection, in contrast to many other viral diseases.…”

Section: Discussionmentioning

confidence: 99%

“…In previous papers, it was shown that there was 19% subclinical infection with Junin virus among high-risk laboratory workers who routinely handled the virus [Weissenbacher et al, 1976;Weissenbacher et al, 1978;Weissenbacher et al, 19801.…”

Section: Most Human Viral Diseases Have Widely Varying Rates Of Inappmentioning

confidence: 99%

Junin virus activity in two rural populations of the Argentine hemorrhagic fever (AHF) endemic area

Weissenbacher

Sabattini

Ávila

et al. 1983

Journal of Medical Virology

View full text Add to dashboard Cite

To determine the prevalence of inapparent infection with Junin virus among the rural population and its relation to the clinical disease, a serological study was carried out in two zones of the endemic area of Argentine hemorrhagic fever (AHF). From the first appearance of AHF in the zones (1963) and the moment of the survey (1977), 14 years had passed. A total of 695 serum samples were obtained, 540 from Córdoba and 155 from Buenos Aires. Of the 695 serum samples, 83 were positive for neutralizing antibodies against Junin virus. Total infection (clinical and inapparent cases) reached 11.6% and 12.03% in the Buenos Aires and Córdoba zones, respectively, showing that the total prevalence of infection in two zones separated by 320 miles, are very much alike. In Córdoba province, the prevalence of clinical infection was 7.59%, while that for inapparent infection was 4.44%. Values for the Province of Buenos Aires were 9.67% and 1.93%, respectively. In addition to a low prevalence of inapparent infections, the results of this survey show that roughly 90% of the population is susceptible to contract the disease; this stresses the need to immunize susceptible individuals in the endemic area.

show abstract

“…Seroepidemiological surveys demonstrated a low prevalence of inapparent or subclinical human infections with JUNV, 10,11 but the regular consequence of human infection with JUNV is the development of signs and symptoms to allow the presumptive diagnosis of FHA, a disease originally described by Arribalzaga in 1955. 12 Confirmatory diagnosis is made by JUNV isolation and/or specific serological conversion.…”

Section: The Diseasementioning

confidence: 99%